The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is investigating whether randomization to perioperative darbepoetin alfa treatment improves the rehabilitation following surgery for colonic and rectal cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herning Hospital
• Collaborator: Amgen
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• Planned colonic and rectal surgery because of presumed cancer disease in the colon and rectum

Exclusion Criteria:

• Psychiatric disease or dementia

• Diseases, that renders participation in the study impossible

• Thromboembolic disease within the last three months

• Dysregulated hypertension (systolic blood pressure>175 mmHg and/or diastolic blood pressure>105 mmHg)

• Other diseases or causes that will contraindicate treatment with Darbepoetin Alfa

• Other diseases or causes that will contraindicate further treatment with Darbepoetin Alfa

• Patients that preoperatively and/or four days postoperatively have a hemoglobin concentration > 14 g/dl

• Former cancer disease

• Disseminated cancer disease

• Rectal cancer stage T4